Report cover image

Vital Proteins for Biomanufacturing Market by Groups (Cytokines, Enzymes & Chemicals, Expression Systems), Function (Diagnostics, Drug Discovery & Development), Indication - Global Forecast 2024-2030

Publisher 360iResearch
Published Jan 15, 2024
Length 187 Pages
SKU # IRE18451571

Description

Vital Proteins for Biomanufacturing Market by Groups (Cytokines, Enzymes & Chemicals, Expression Systems), Function (Diagnostics, Drug Discovery & Development), Indication - Global Forecast 2024-2030


The Vital Proteins for Biomanufacturing Market size was estimated at USD 52.10 billion in 2023 and expected to reach USD 56.52 billion in 2024, at a CAGR 8.92% to reach USD 94.81 billion by 2030.

Global Vital Proteins for Biomanufacturing MarketVital proteins for biomanufacturing encompasses the production, distribution, and utilization of essential protein products derived from biological sources that have significant applications in various industries, such as pharmaceuticals, biotechnology, and medicine. These proteins are integral to cell growth, development, and overall function in living organisms. They also play a crucial role in manufacturing biopharmaceuticals, diagnostics, vaccines, cell therapies, and other biomaterial products. Increasing demand for biopharmaceuticals with enhanced therapeutic efficacy, advancements in recombinant DNA technology allowing high-level expression of foreign genes, and rapid adoption of novel cell culture platforms to produce complex biotherapeutics significantly drive the market growth. However, high capital expenditure requirements for establishing state-of-the-art biomanufacturing facilities and complexities associated with scaling up production processes may hinder market adoption. Adopting artificial intelligence (AI) and machine learning algorithms can accelerate protein design, improve yields, and optimize process conditions, and investments in advanced analytical techniques are expected to create a lucrative market opportunity in the forecast period.

Regional Insights

The Americas has a significant presence in the vital proteins for the Biomanufacturing market due to substantial investments by key players to enhance their capabilities in the market. Regulatory agencies, including the U.S. FDA and Health Canada, work diligently to meet safety standards and have implemented guidelines governing Good Manufacturing Practices(GMPs) for vital protein production. The European Union and the United Kingdom boast strong biotech sectors supported by robust R&D capabilities. The Middle East & Africa region has observed massive growth in recent years due to raised investment in healthcare infrastructure. The Asia-Pacific (APAC) region holds significant potential in the biomanufacturing sector, particularly in the field of vital proteins, which can be attributed to various factors such as rapid advancements in technology, expanding pharmaceutical and biotechnology industries, favorable government policies, and increased investments in research and development.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Vital Proteins for Biomanufacturing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Vital Proteins for Biomanufacturing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Vital Proteins for Biomanufacturing Market, highlighting leading vendors and their innovative profiles. These include Abcam PLC, Abnova Corporation, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., BioLegend, Inc. by PerkinElmer, Inc., Biologics International Corporation, BPS Bioscience, Inc., Bristol-Myers Squibb Company, Creative BioMart Inc., Croyez Bioscience Co., Ltd., Eli Lilly and Company, Enzo Life Sciences, Inc., GenScript Biotech Corporation, Johnson & Johnson Services, Inc., Laurus Bio Private Limited, LenioBio GmbH, Lonza Group AG, Merck KGaA, Meridian Bioscience, Inc. by SD Biosensor Inc., Miltenyi Biotec B.V. & Co. KG, Novartis AG, ProMab Biotechnologies, Inc., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Vital Proteins for Biomanufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

Groups
Cytokines
Chemokines

Colony-stimulating factors

Interferons

Interleukins

Tumor necrosis factors
Enzymes & Chemicals
DNA Capping Enzymes

Endonucleases

Glycosidases

Polyadenylation Enzymes

Protease Inhibitors

Transcription Enzymes
Expression Systems
Bacterial

Insect

Mammalian Cells

Yeast
Media & Supplements
Albumin

Epidermal Growth Factor (EGF)

Fibroblast Growth Factors (FGFs)

Insulin-like Growth Factors (IGFs)

Transferrin

Vascular Endothelial Growth Factor (VEGF)
Protein A Resins
Quality Control Reagents
Vectors & Transfection Reagents
Function
Diagnostics
Drug Discovery & Development
Biologics

Cell & Gene Therapy

Vaccines
Indication
Autoimmune Disorders
Infectious Diseases
Oncology
Rare Genetic Disorders
Region
Americas
Argentina

Brazil

Canada

Mexico

United States
California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas
Asia-Pacific
Australia

China

India

Indonesia

Japan

Malaysia

Philippines

Singapore

South Korea

Taiwan

Thailand

Vietnam
Europe, Middle East & Africa
Denmark

Egypt

Finland

France

Germany

Israel

Italy

Netherlands

Nigeria

Norway

Poland

Qatar

Russia

Saudi Arabia

South Africa

Spain

Sweden

Switzerland

Turkey

United Arab Emirates

United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Vital Proteins for Biomanufacturing Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Vital Proteins for Biomanufacturing Market?
3. What are the technology trends and regulatory frameworks in the Vital Proteins for Biomanufacturing Market?
4. What is the market share of the leading vendors in the Vital Proteins for Biomanufacturing Market?
5. Which modes and strategic moves are suitable for entering the Vital Proteins for Biomanufacturing Market?

Note: PDF & Excel + Online Access - 1 Year

Table of Contents

187 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Vital Proteins for Biomanufacturing Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing demand for biopharmaceuticals with enhanced therapeutic efficacy
5.1.1.2. Rapid adoption of novel cell culture platforms to produce complex biotherapeutics
5.1.1.3. Growing interest in personalized medicine necessitates tailored protein therapeutics
5.1.2. Restraints
5.1.2.1. High capital expenditure requirements for establishing state-of-the-art biomanufacturing facilities
5.1.3. Opportunities
5.1.3.1. Supportive government policies promoting investments in research & development
5.1.3.2. Ongoing collaborations between academia & industry players for technological innovations in vital proteins
5.1.4. Challenges
5.1.4.1. Complexities associated with scaling up production processes
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Vital Proteins for Biomanufacturing Market, by Groups
6.1. Introduction
6.2. Cytokines
6.3.1. Chemokines
6.3.2. Colony-stimulating factors
6.3.3. Interferons
6.3.4. Interleukins
6.3.5. Tumor necrosis factors
6.3. Enzymes & Chemicals
6.4.1. DNA Capping Enzymes
6.4.2. Endonucleases
6.4.3. Glycosidases
6.4.4. Polyadenylation Enzymes
6.4.5. Protease Inhibitors
6.4.6. Transcription Enzymes
6.4. Expression Systems
6.5.1. Bacterial
6.5.2. Insect
6.5.3. Mammalian Cells
6.5.4. Yeast
6.5. Media & Supplements
6.6.1. Albumin
6.6.2. Epidermal Growth Factor (EGF)
6.6.3. Fibroblast Growth Factors (FGFs)
6.6.4. Insulin-like Growth Factors (IGFs)
6.6.5. Transferrin
6.6.6. Vascular Endothelial Growth Factor (VEGF)
6.6. Protein A Resins
6.7. Quality Control Reagents
6.8. Vectors & Transfection Reagents
7. Vital Proteins for Biomanufacturing Market, by Function
7.1. Introduction
7.2. Diagnostics
7.3. Drug Discovery & Development
7.4.1. Biologics
7.4.2. Cell & Gene Therapy
7.4.3. Vaccines
8. Vital Proteins for Biomanufacturing Market, by Indication
8.1. Introduction
8.2. Autoimmune Disorders
8.3. Infectious Diseases
8.4. Oncology
8.5. Rare Genetic Disorders
9. Americas Vital Proteins for Biomanufacturing Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Vital Proteins for Biomanufacturing Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Vital Proteins for Biomanufacturing Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
12.3.1. Merger & Acquisition
12.3.1.1. Everest Medicines Ltd. acquires rights to 3C-like protease inhibitors to develop antivirals for COVID-19
12.3.2. New Product Launch & Enhancement
12.3.2.1. New England Biolabs Introduces Faustovirus Capping Enzyme, a Novel Enzymatic mRNA Capping Solution for mRNA Manufacturing
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Abcam PLC
13.1.2. Abnova Corporation
13.1.3. Agilent Technologies, Inc.
13.1.4. Bio-Rad Laboratories, Inc.
13.1.5. BioLegend, Inc. by PerkinElmer, Inc.
13.1.6. Biologics International Corporation
13.1.7. BPS Bioscience, Inc.
13.1.8. Bristol-Myers Squibb Company
13.1.9. Creative BioMart Inc.
13.1.10. Croyez Bioscience Co., Ltd.
13.1.11. Eli Lilly and Company
13.1.12. Enzo Life Sciences, Inc.
13.1.13. GenScript Biotech Corporation
13.1.14. Johnson & Johnson Services, Inc.
13.1.15. Laurus Bio Private Limited
13.1.16. LenioBio GmbH
13.1.17. Lonza Group AG
13.1.18. Merck KGaA
13.1.19. Meridian Bioscience, Inc. by SD Biosensor Inc.
13.1.20. Miltenyi Biotec B.V. & Co. KG
13.1.21. Novartis AG
13.1.22. ProMab Biotechnologies, Inc.
13.1.23. Thermo Fisher Scientific Inc.
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
FIGURE 1. VITAL PROTEINS FOR BIOMANUFACTURING MARKET RESEARCH PROCESS
FIGURE 2. VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, 2023 VS 2030
FIGURE 3. VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. VITAL PROTEINS FOR BIOMANUFACTURING MARKET DYNAMICS
FIGURE 7. VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2023 VS 2030 (%)
FIGURE 8. VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2023 VS 2030 (%)
FIGURE 10. VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 12. VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. VITAL PROTEINS FOR BIOMANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. VITAL PROTEINS FOR BIOMANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.